Licaminlimab for Dry Eye Syndrome

(PREDICT-1 Trial)

Recruiting at 9 trial locations

Overseen By Oculis Chief Development Officer

Age: 18+

Sex: Any

Trial Phase: Phase 2 & 3

Sponsor: Oculis

Disqualifiers: Disorders interfering with study, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 6

Duration: 8 weeks

160 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.

Are You a Good Fit for This Trial?

Inclusion Criteria

I agree to have my genes tested.

I meet a main requirement for the study.

I was diagnosed with Dry Eye Disease in the past 6 months.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either licaminlimab or vehicle ophthalmic solution

8 weeks

4 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

2 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• Licaminlimab

How Is the Trial Designed?

Group I: licaminlimab Experimental Treatment 2 Interventions

60 mg/mL licaminlimab ophthalmic solution

Group II: Vehicle Placebo Group 2 Interventions

Vehicle of licaminlimab ophthalmic solution

Who Is Running the Clinical Trial?

Oculis

Lead Sponsor

Trials

9

Recruited

1,700+